Department of Biostatistics, Vanderbilt University Medical Center, Nashville, Tennessee.
Department of Public Health, Grand Valley State University, Grand Rapids, Michigan.
Cancer. 2021 Jun 1;127(11):1758-1769. doi: 10.1002/cncr.33425. Epub 2021 Mar 11.
Robust and reliable prognosis prediction models have not been developed and validated for Asian patients with breast cancer, a rapidly growing yet understudied population in the United States.
We used longitudinal data from the Shanghai Breast Cancer Survival Study, a population-based prospective cohort study (n = 5042), to develop prediction models for 5- and 10-year disease-free survival (DFS) and overall survival (OS). The initial models considered age at diagnosis, tumor grade, tumor size, number of positive nodes, TNM stage, chemotherapy, tamoxifen therapy, and estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth factor receptor 2 (HER2) status. We then evaluated whether the addition of modifiable lifestyle factors (physical activity, soy isoflavones intake, and postdiagnostic weight change) improved the models. All final models have been validated internally and externally in the National Cancer Database when applicable.
Our final models included age at diagnosis, tumor grade, tumor size, number of positive nodes, TNM stage, chemotherapy, tamoxifen therapy, ER status, PR status, 6-month postdiagnostic weight change, interaction between ER status and tamoxifen therapy, and interaction between age and TNM stage. The internal validation yielded C-statistics of 0.76, 0.74, 0.78, and 0.75 for 5-year DFS, 10-year DFS, 5-year OS, and 10-year OS, respectively. The external validation yielded C-statistics of 5- and 10-year OS both at 0.78 for Chinese ethnicity, 0.79 for East Asian ethnicity, and 0.75 and 0.76 for all ethnic groups combined.
We developed prediction models for breast cancer prognosis from a large prospective study. Our prognostic models performed very well in women from the United States-particularly in Asian American women-and demonstrated high prediction accuracy and generalizability.
在美国,亚洲乳腺癌患者是一个快速增长但研究不足的人群,目前尚未开发和验证针对该人群的稳健可靠的预后预测模型。
我们使用来自上海乳腺癌生存研究的纵向数据,这是一项基于人群的前瞻性队列研究(n=5042),为 5 年和 10 年无病生存(DFS)和总生存(OS)开发预测模型。初始模型考虑了诊断时的年龄、肿瘤分级、肿瘤大小、阳性淋巴结数、TNM 分期、化疗、他莫昔芬治疗以及雌激素受体(ER)、孕激素受体(PR)和人表皮生长因子受体 2(HER2)状态。然后,我们评估了是否可以通过添加可改变的生活方式因素(体力活动、大豆异黄酮摄入和诊断后体重变化)来改善模型。所有最终模型都已在适用时在国家癌症数据库中进行了内部和外部验证。
我们的最终模型包括诊断时的年龄、肿瘤分级、肿瘤大小、阳性淋巴结数、TNM 分期、化疗、他莫昔芬治疗、ER 状态、PR 状态、诊断后 6 个月体重变化、ER 状态和他莫昔芬治疗之间的相互作用以及年龄和 TNM 分期之间的相互作用。内部验证得到的 5 年 DFS、10 年 DFS、5 年 OS 和 10 年 OS 的 C 统计量分别为 0.76、0.74、0.78 和 0.75。外部验证得到的中国人群的 5 年和 10 年 OS 的 C 统计量均为 0.78,东亚人群为 0.79,所有人群的 5 年和 10 年 OS 的 C 统计量均为 0.75 和 0.76。
我们从一项大型前瞻性研究中开发了用于乳腺癌预后的预测模型。我们的预后模型在美国女性中表现非常出色-尤其是在亚裔美国女性中-并且表现出较高的预测准确性和通用性。